Andrea Alimonti, MD

Andrea Alimonti, MD
About Andrea Alimonti, MD

Dr. Alimonti’s research is focused on the characterization of a novel type of cellular senescence response which is elicited by complete loss of the tumor suppressor PTEN, and on the identification of novel compounds with pro-senescence activity. The final aim is to develop the concept of pro-senescence therapy for cancer, from experimental evidences to clinic, investigating the efficacy of “pro-senescence” compounds in phase I clinical trials. This will also allow for the identification of senescence markers in human tumor samples to be used in clinic.

Designation: Group Leader

Institute of Oncology Research